Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Savitz

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Neuropsychiatric Disease and Treatment|March 14, 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European populationAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Neuropsychiatric Disease and Treatment|December 1, 2018
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitateMaju Mathews, Isaac Nuamah, Adam J Savitz, et al.
Translational Psychiatry|August 16, 2012
Epistasis network centrality analysis yields pathway replication across two GWAS cohorts for bipolar disorderA Pandey, N A Davis, B C White, et al.
Neuropsychiatric Disease and Treatment|July 2, 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized StudiesMaju Mathews, Srihari Gopal, Arun Singh, et al.
Neuropsychiatric Disease and Treatment|June 14, 2019
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophreniaMaju Mathews, Srihari Gopal, Isaac Nuamah, et al.
The International Journal of Neuropsychopharmacology|February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Psychiatry Research|January 19, 2016
An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophreniaAnthony O Ahmed, Christopher F Murphy, Vassilios Latoussakis, et al.
The Journal of Clinical Psychiatry|September 6, 2024
Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled TrialsJoshua T Jordan, Li Shen, Nicholas J Cooper, et al.
Neuropsychiatric Disease and Treatment|September 2, 2017
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
NPJ Schizophrenia|June 29, 2018
The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH dataMarsha A Wilcox, Adam J Savitz, Anjené M Addington, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Neuropsychiatric Disease and Treatment|March 14, 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European populationAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Neuropsychiatric Disease and Treatment|December 1, 2018
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitateMaju Mathews, Isaac Nuamah, Adam J Savitz, et al.
Translational Psychiatry|August 16, 2012
Epistasis network centrality analysis yields pathway replication across two GWAS cohorts for bipolar disorderA Pandey, N A Davis, B C White, et al.
Neuropsychiatric Disease and Treatment|July 2, 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized StudiesMaju Mathews, Srihari Gopal, Arun Singh, et al.
Neuropsychiatric Disease and Treatment|June 14, 2019
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophreniaMaju Mathews, Srihari Gopal, Isaac Nuamah, et al.
The International Journal of Neuropsychopharmacology|February 24, 2016
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority StudyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
Psychiatry Research|January 19, 2016
An examination of neurocognition and symptoms as predictors of post-hospital community tenure in treatment resistant schizophreniaAnthony O Ahmed, Christopher F Murphy, Vassilios Latoussakis, et al.
The Journal of Clinical Psychiatry|September 6, 2024
Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled TrialsJoshua T Jordan, Li Shen, Nicholas J Cooper, et al.
Neuropsychiatric Disease and Treatment|September 2, 2017
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority studyAdam J Savitz, Haiyan Xu, Srihari Gopal, et al.
NPJ Schizophrenia|June 29, 2018
The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH dataMarsha A Wilcox, Adam J Savitz, Anjené M Addington, et al.
Pageof 4